- Home
- MFIN vs DERM Comparison
MFIN vs DERM Comparison
Compare MFIN & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | DERM |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.4M | 210.0M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MFIN | DERM |
|---|---|---|
| Price | $10.03 | $8.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $12.67 |
| AVG Volume (30 Days) | 37.1K | ★ 146.9K |
| Earning Date | 03-03-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | ★ 1.06 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $338,783,000.00 | $59,399,000.00 |
| Revenue This Year | N/A | $17.48 |
| Revenue Next Year | $5.83 | $55.83 |
| P/E Ratio | $5.93 | ★ N/A |
| Revenue Growth | ★ 15.53 | 2.82 |
| 52 Week Low | $7.71 | $3.86 |
| 52 Week High | $10.98 | $9.56 |
Technical Indicators
Market Signals| Indicator | MFIN | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 58.22 |
| Support Level | $10.01 | $8.02 |
| Resistance Level | $10.24 | $9.56 |
| Average True Range (ATR) | 0.25 | 0.59 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 48.37 | 64.45 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.